Recently, outstanding clinical results have demonstrated the power of the immune system to eradicate cancer. However current cancer immunotherapy using immune checkpoint (IC) inhibitors has cured only a minority of patients The frequent failure of cancer immunotherapy to cure patients has been attributed to the lack of tumor-specific CD8+ T cells and/or IC expression at the tumor site and to the immunosuppressive tumor microenvironment
Basic research to produce new TLR3 ligands
Toll-like Receptor 3 (TLR3) was recognized in 2001 as an Pattern Recognition Receptor that binds to extracellular, virus-derived, double-stranded RNA (dsRNA) and triggers the secretion of cytokines, including type I interferons. TLR3 ligands are powerful immune adjuvants that activate antigen-presenting cells (dendritic cells and macrophages) (Alexopoulou et al., 2001) and induces strong CD8+ T lymphocytes priming.
New TLR3 ligands enables patient’s immune system
for personalized cancer immunotherapy.
41 quai Fulchiron
69005 Lyon, FRANCE
+33 (0)4 78 04 30 90